Awakn Life Sciences Corp.



dynaCERT Inc.
Latest Comments
image_pdfimage_print

Awakn Life Sciences’ new psychedelic drug treatment for alcohol addiction moving to clinical trial

As we all know alcohol addiction is one of the worst addictions in society costing billions per year. A 2010 […]


Awakn announces first-ever study investigating ketamine in gambling addiction treatment

When we think about addiction many people think about drugs, tobacco, and alcohol addiction; but often forget about gambling addiction. […]


Awakn researching psychedelics for a better future

Whether you are familiar with it or not there have been relatively rapid advancements in health care and research utilizing […]


Awakn Life Sciences’ Anthony Tennyson on using researched backed psychedelic drugs and therapies to treat Alcohol Use Disorder

In a recent InvestorIntel interview, Tracy Weslosky speaks with Anthony Tennyson, CEO of Awakn Life Sciences Corp. (NEO: AWKN) about […]


Anthony Tennyson on Awakn Life Sciences bringing innovation in addiction treatment to the market

In a recent InvestorIntel interview, Tracy Weslosky speaks with Anthony Tennyson, CEO of Awakn Life Sciences Corp. (NEO: AWKN) about […]


Newly listed Awakn Life Sciences’ team of experts prepare a pathway to treat addiction through psychedelic medicines

One of the largest problems in our society today is substance abuse and addiction. Almost 21 million Americans have at […]